advertisement
Rowe-Rendleman CL 3
Showing records 1 to 3 | Display only abstracts from Rowe-Rendleman CL in IGR 18-274091 Making Basic Science Studies in Glaucoma More Clinically Relevant: The Need for a Consensus
Toris CB; Gelfman C; Whitlock A; Sponsel WE; Rowe-Rendleman CL
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 501-518 (IGR: 19-1)
69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Harris A; Ward CL; Rowe-Rendleman CL; Ouchi T; Wood A; Fujii A; Serle JB
Journal of Glaucoma 2016; 25: e826-e833 (IGR: 18-2)
65800 A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers
Suto F; Rowe-Rendleman CL; Ouchi T; Jamil A; Wood A; Ward CL
Investigative Ophthalmology and Visual Science 2015; 56: 7963-7970 (IGR: 17-3)
